Rithim Biologics®, Inc.

    • Founded in March, 2016, Rithim Biologics® is a privately held, early stage startup company developing gene therapies to treat tachycardias (fast heart rates) in humans.
    • Utilizing gene therapies, our initial efforts are targeting atrial fibrillation (AF) and more specifically those patients at risk for post-operative (cardiac) AF (POAF).
    • POAF has been reported in 27% to 40% of coronary artery bypass graph (CABG) surgery patients.1 Worldwide, approximately 800,000 patients undergo CABG procedures annually.2
    • Postop AF has been reported in 14% to 60% of Valve Surgery patients.3 Worldwide, approximately 360,000 patients undergo heart valve surgery.4
    • Considering all patients with any type of AF, in the United States alone it is estimated to be a $26 billion burden on healthcare.5


1 Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangano DT. A Multicenter Risk Index for Atrial Fibrillation. After Cardiac Surgery JAMA, April 14, 2004—Vol 291, No. 14 p. 1720
2 Filardo G , Damiano RJ Jr , Ailawadi G , Thourani VH , Pollock BD , Sass DM , Phan TK , Nguyen H , da Graca B. Epidemiology of new-onset atrial fibrillation following coronary artery bypass graft surgery. Heart. 2018 Jan 11.
3 Tanawuttiwat T, et al. New-Onset Atrial Fibrillation After Aortic Valve Replacement – Comparison of Transfemoral, Transapical, Transaortic, and Surgical Approaches. JACC, April 22, 2014 – Vol 63, No. 15 p.1510
4 Calculations based on Business Reports from Star Tribune, Medtronic Earnings , American Heart Association
5 Mozaffarian D, et al. Circulation 2016;133:e38-360.